PharmaNeuroBoost’s lead product in major depression receives IND approval from FDA

30-Jun-2010 - Belgium

PharmaNeuroBoost NV (PNB) reported that the U.S. food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for PNB01. PNB01 is a proprietary owned, fixed dose combination of citalopram and low dose pipamperone, and is under development for the treatment of major depressive disorder. The IND approval permits PharmaNeuroBoost to initiate a Phase I clinical trial in healthy volunteers in the US.

Previously, promising results with PNB01 over standard of care citalopram have been obtained in a UK Phase II Proof of Concept trial in patients with moderate to severe Major Depressive Disorder. PNB is currently analyzing the data of its successful European Phase II study in MDD and planning late stage development of PNB01. PharmaNeuroBoost NV, founded in 2006, is a biopharmaceutical company located in Belgium, dedicated to developing best in class CNS therapeutics, based on solid intellectual property. The company’s primary goal is to significantly improve current therapy targeted against mood, anxiety, and psychotic disorders. The two front-running clinical stage proprietary projects (PNB01 and PNB02) are targeted against major depression and schizophrenia, respectively.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

WITec opens new regional headquarters in Singapore

A 'bio-refinery': using the chemistry of willow trees to treat municipal wastewater - Millions of litres of primary municipal wastewater can be treated sustainably using fast-growing willow trees while also producing renewable bioenergy and ‘green’ chemicals

A 'bio-refinery': using the chemistry of willow trees to treat municipal wastewater - Millions of litres of primary municipal wastewater can be treated sustainably using fast-growing willow trees while also producing renewable bioenergy and ‘green’ chemicals

Lymphoma overrides a key protein's quadruple locks

TxCell presents final positive results of the phase I/II clinical trial with antigen-specific Treg cells in Crohn’s disease

Two known chemotherapy agents effectively target breast cancer stem cells

Psilocybin eases existential anxiety in people with life-threatening cancer

Anti-cancer drug brewed from reprogrammed yeast - Engineered yeast cells can synthetically produce the essential cancer medicine vinblastine, an international team of scientists proved

Anti-cancer drug brewed from reprogrammed yeast - Engineered yeast cells can synthetically produce the essential cancer medicine vinblastine, an international team of scientists proved

Study reveals how 'forever chemicals' may impact heart health in older women - "Our results show you can’t lump all PFAS together"

Study reveals how 'forever chemicals' may impact heart health in older women - "Our results show you can’t lump all PFAS together"

Neovacs achieves key clinical milestones

Cougar Biotechnology Announces Initiation of Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breast Cancer Patients

Stratagene Acquires Rights to microRNA Sequences - Co-Exclusive License Provides Access to More Than 150 microRNA Sequences for the Development, Manufacture and Sale of Molecular Diagnostic Kits

Retina-on-a-chip provides powerful tool for studying eye disease

Retina-on-a-chip provides powerful tool for studying eye disease